Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias

A. E. Frankel, J. A. McCubrey, M. S. Miller, S. Delatte, J. Ramage, M. Kiser, G. L. Kucera, R. L. Alexander, M. Beran, E. P. Tagge, R. J. Kreitman, D. E. Hogge

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Leukemic blasts from patients with acute phase chronic myeloid leukemic and refractory acute myeloid leukemia are highly resistant to a number of cytotoxic drugs. To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors. The DTLIL3 construct was more cytotoxic to interleukin-3 receptor (IL3R) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation, growth in semi-solid medium and induction of apoptosis. Exposure of mononuclear cells to 680 pM DTLIL3 for 48 h in culture reduced the number of cells capable of forming colonies in semi-solid medium (colony-forming units leukemia) ≥ 10-fold in 4/11 (36%) patients with myeloid acute phase chronic myeloid leukemia (CML) and 3/9 (33%) patients with acute myeloid leukemia (AML). Normal myeloid progenitors (colony-forming unit granulocyte-macrophage) from five different donors treated and assayed under identical conditions showed intermediate sensitivity with three- to five-fold reductions in colonies. The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease.

Original languageEnglish (US)
Pages (from-to)576-585
Number of pages10
JournalLeukemia
Volume14
Issue number4
StatePublished - 2000

Fingerprint

Diphtheria Toxin
Myeloid Leukemia
Interleukin-3
Poisons
Leukemia, Myeloid, Chronic Phase
Acute Myeloid Leukemia
Leukemia
Interleukin-3 Receptors
Cell Line
Granulocyte-Macrophage Progenitor Cells
Diphtheria
Multiple Drug Resistance
Proxy
Myeloid Cells
Recombinant Proteins
Thymidine
Stem Cells
Cell Count
Tissue Donors
Apoptosis

Keywords

  • Acute myeloid leukemia
  • Chronic myeloid leukemia
  • Diphtheria fusion toxin
  • Interleukin-3

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Frankel, A. E., McCubrey, J. A., Miller, M. S., Delatte, S., Ramage, J., Kiser, M., ... Hogge, D. E. (2000). Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia, 14(4), 576-585.

Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. / Frankel, A. E.; McCubrey, J. A.; Miller, M. S.; Delatte, S.; Ramage, J.; Kiser, M.; Kucera, G. L.; Alexander, R. L.; Beran, M.; Tagge, E. P.; Kreitman, R. J.; Hogge, D. E.

In: Leukemia, Vol. 14, No. 4, 2000, p. 576-585.

Research output: Contribution to journalArticle

Frankel, AE, McCubrey, JA, Miller, MS, Delatte, S, Ramage, J, Kiser, M, Kucera, GL, Alexander, RL, Beran, M, Tagge, EP, Kreitman, RJ & Hogge, DE 2000, 'Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias', Leukemia, vol. 14, no. 4, pp. 576-585.
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14(4):576-585.
Frankel, A. E. ; McCubrey, J. A. ; Miller, M. S. ; Delatte, S. ; Ramage, J. ; Kiser, M. ; Kucera, G. L. ; Alexander, R. L. ; Beran, M. ; Tagge, E. P. ; Kreitman, R. J. ; Hogge, D. E. / Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. In: Leukemia. 2000 ; Vol. 14, No. 4. pp. 576-585.
@article{071998d8f69544c399bb6cac931e31a8,
title = "Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias",
abstract = "Leukemic blasts from patients with acute phase chronic myeloid leukemic and refractory acute myeloid leukemia are highly resistant to a number of cytotoxic drugs. To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors. The DTLIL3 construct was more cytotoxic to interleukin-3 receptor (IL3R) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation, growth in semi-solid medium and induction of apoptosis. Exposure of mononuclear cells to 680 pM DTLIL3 for 48 h in culture reduced the number of cells capable of forming colonies in semi-solid medium (colony-forming units leukemia) ≥ 10-fold in 4/11 (36{\%}) patients with myeloid acute phase chronic myeloid leukemia (CML) and 3/9 (33{\%}) patients with acute myeloid leukemia (AML). Normal myeloid progenitors (colony-forming unit granulocyte-macrophage) from five different donors treated and assayed under identical conditions showed intermediate sensitivity with three- to five-fold reductions in colonies. The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease.",
keywords = "Acute myeloid leukemia, Chronic myeloid leukemia, Diphtheria fusion toxin, Interleukin-3",
author = "Frankel, {A. E.} and McCubrey, {J. A.} and Miller, {M. S.} and S. Delatte and J. Ramage and M. Kiser and Kucera, {G. L.} and Alexander, {R. L.} and M. Beran and Tagge, {E. P.} and Kreitman, {R. J.} and Hogge, {D. E.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "576--585",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias

AU - Frankel, A. E.

AU - McCubrey, J. A.

AU - Miller, M. S.

AU - Delatte, S.

AU - Ramage, J.

AU - Kiser, M.

AU - Kucera, G. L.

AU - Alexander, R. L.

AU - Beran, M.

AU - Tagge, E. P.

AU - Kreitman, R. J.

AU - Hogge, D. E.

PY - 2000

Y1 - 2000

N2 - Leukemic blasts from patients with acute phase chronic myeloid leukemic and refractory acute myeloid leukemia are highly resistant to a number of cytotoxic drugs. To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors. The DTLIL3 construct was more cytotoxic to interleukin-3 receptor (IL3R) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation, growth in semi-solid medium and induction of apoptosis. Exposure of mononuclear cells to 680 pM DTLIL3 for 48 h in culture reduced the number of cells capable of forming colonies in semi-solid medium (colony-forming units leukemia) ≥ 10-fold in 4/11 (36%) patients with myeloid acute phase chronic myeloid leukemia (CML) and 3/9 (33%) patients with acute myeloid leukemia (AML). Normal myeloid progenitors (colony-forming unit granulocyte-macrophage) from five different donors treated and assayed under identical conditions showed intermediate sensitivity with three- to five-fold reductions in colonies. The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease.

AB - Leukemic blasts from patients with acute phase chronic myeloid leukemic and refractory acute myeloid leukemia are highly resistant to a number of cytotoxic drugs. To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors. The DTLIL3 construct was more cytotoxic to interleukin-3 receptor (IL3R) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation, growth in semi-solid medium and induction of apoptosis. Exposure of mononuclear cells to 680 pM DTLIL3 for 48 h in culture reduced the number of cells capable of forming colonies in semi-solid medium (colony-forming units leukemia) ≥ 10-fold in 4/11 (36%) patients with myeloid acute phase chronic myeloid leukemia (CML) and 3/9 (33%) patients with acute myeloid leukemia (AML). Normal myeloid progenitors (colony-forming unit granulocyte-macrophage) from five different donors treated and assayed under identical conditions showed intermediate sensitivity with three- to five-fold reductions in colonies. The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease.

KW - Acute myeloid leukemia

KW - Chronic myeloid leukemia

KW - Diphtheria fusion toxin

KW - Interleukin-3

UR - http://www.scopus.com/inward/record.url?scp=0034119046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034119046&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 576

EP - 585

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -